Epitalon

Two different things are called Epitalon in casual use, and keeping them apart is most of the work of reading this literature.

Epithalamin is a polypeptide extract of bovine pineal gland, made in St Petersburg from the 1970s onwards. Epitalon (also Epithalon, AEDG) is a synthetic tetrapeptide, Ala-Glu-Asp-Gly, designed from the amino acid composition of that extract on the theory that a short peptide carries the activity [1][7]. In 2017 the same group used mass spectrometry to show AEDG is genuinely present among the tetrapeptides of the pineal polypeptide complex, which closes that loop [2].

The telomerase claim. In 2003 Khavinson and colleagues added Epithalon to telomerase-negative human fetal fibroblasts and reported induction of the catalytic subunit, telomerase enzyme activity and telomere elongation [3]. A follow-up in 2004 found treated fibroblasts pushed ten passages past the point where controls stopped dividing [8]. For twenty years those two papers, from one laboratory, were the whole basis of the claim. In 2025 a group at Brunel University tested it independently across normal epithelial and fibroblast cells and two breast cancer lines, and found dose-dependent telomere lengthening: through hTERT and telomerase upregulation in the normal cells, and through the alternative lengthening of telomeres pathway in the cancer cells [4]. That paper carries a published correction [9]. This is still cell culture — but it is no longer a single-laboratory result, which is more than can be said for most of this category.

The human trials, and what they actually tested. The Kiev group of Korkushko and Khavinson ran long randomised studies in elderly patients with coronary disease and accelerated cardiovascular ageing. At 12 years, deaths in the treated group were 28% lower and cardiovascular mortality roughly half [5]; a 15-year follow-up of 39 treated against 40 control patients reported decelerated cardiovascular ageing, preserved physical endurance, normalised melatonin rhythm and lower mortality [6]. A separate randomised study reported improved lipids and lower 24-hour blood pressure in older women with ischaemic heart disease and hypertension [10]. All of these used Epithalamin, the extract. A randomised study of melatonin rhythm in healthy elderly subjects also used the extract, and found it modulated rather than simply raised melatonin: it went up in those whose pineal function was already low and tended to fall in those with normal function [11].

The tetrapeptide itself does appear in human work. A 2007 Russian-language report describes both Epithalamin and Epitalon restoring night melatonin release in old monkeys and raising night melatonin in elderly people with pineal insufficiency [12], and the 2002 monograph reports improved visual function in patients with pigmentary retinal degeneration [7]. These are not controlled trials with reported effect sizes, and they are not independent of the group that developed the compound.

Animal work. Epitalon restores circadian melatonin and cortisol rhythms in old rhesus monkeys, increases lifespan in mice and fruit flies, and prolongs retinal function in a rat model of retinitis pigmentosa, all reported within the same programme [7][13]. Pineal peptides restored age-related disturbances in pineal and pancreatic hormone function in rats [14], and both preparations raised antioxidant enzyme activity in old rats [15][16]. In stressed rats, intranasal Epitalon changed c-Fos expression in pinealocytes [17].

The proposed mechanism is direct and unusual: the peptide is small enough to enter cells and the nucleus, and it binds DNA and chromatin in a sequence-selective way, changing gene expression.

The evidence for that is real but indirect. Fluorescently labelled Epithalon showed up in the cytoplasm, nucleus and nucleolus of HeLa cells; in vitro it quenched the fluorescence of labelled oligonucleotides with constants that differed by sequence, binding preferentially to CNG- and CAG-containing sequences and discriminating their cytosine methylation status [18]. Molecular modelling places its binding on histones H1/3 and H1/6, at sites that contact DNA [19]. The same study found AEDG raised expression of the neurogenic markers nestin, GAP43, β-tubulin III and doublecortin by 1.6-1.8 fold in human gingival mesenchymal stem cells, with the protein synthesis to match [19][20]. The group has assembled this into a general "peptide regulation of gene expression" framework covering the whole family of short peptides [21][22][23].

Two things to hold onto. First, sequence-selective binding to naked oligonucleotides in a cuvette is a long way from regulating a gene in a living cell, and the step between them has not been demonstrated. Second, nobody has shown that an injected tetrapeptide with free termini survives in plasma long enough to reach a cell nucleus in a living animal — there is no pharmacokinetic study at all.

The telomerase effect, if it is real in vivo, would be downstream of that: hTERT transcription switched back on in a cell that had silenced it [3][4].

Epitalon is the free tetrapeptide Ala-Glu-Asp-Gly, molecular weight 390, usually supplied lyophilised as the acetate. Epithalamin is a different product entirely: a polypeptide complex extracted from bovine pineal gland, in which free amino acids, dipeptides, tripeptides and tetrapeptides including AEDG have been catalogued by HPLC and mass spectrometry [2].

Routes used in the research literature include intranasal in rats [17] and intramuscular courses for the extract in the human trials [6]. The review literature notes that, despite twenty-five years of biological study, the physicochemical and structural characterisation of the peptide itself remains thin [1].

No adverse effect has been reported in the published human work, and the 2007 report on melatonin rhythm states the pineal preparations had no side effects and could be used in geriatric practice [12]. The long-term trials of the extract, followed to 12 and 15 years, reported lower rather than higher mortality [5][6]. That is a meaningful safety record for the extract, in the population it was studied in.

Three caveats belong with it.

The telomerase question cuts both ways. Reactivating telomerase is the central step by which a somatic cell escapes its replicative limit; it is also what most cancers do. The 2025 replication is explicit that in breast cancer cell lines, Epitalon extended telomeres through the ALT pathway [4]. Nobody has run the experiment that matters — long-term exposure in a living animal with cancer incidence as an endpoint — although the developing group reports anticarcinogenic rather than carcinogenic effects for Epithalamin in rodent models [7]. The honest position is that the mechanism is one that should raise the question, and the question has not been answered independently.

Provenance. The overwhelming majority of the literature on Epitalon and Epithalamin comes from the St Petersburg Institute of Bioregulation and Gerontology and its collaborators, published largely in Bulletin of Experimental Biology and Medicine and Advances in Gerontology, much of it in Russian. Independent replication exists for the cell-culture telomere result [4] and essentially nowhere else.

No pharmacokinetics. There is no study of what happens to the peptide after a dose, in any species.

No interaction studies exist. The mechanistically interesting one is melatonin: Epitalon and Epithalamin are reported to raise the body's own melatonin production in those whose pineal output is low, and to reduce it in those whose output is normal [11][12]. If that modulation is real, stacking it with supplemental melatonin is not simply additive, and neither combination has been tested.

The antioxidant work notes that the pineal peptides act through induction of antioxidant enzymes rather than by direct scavenging, which is a different mechanism from melatonin's [15].